ERBB2 and gastric cancer: For example, trastuzumab, the human epidermal growth factor 2 (HER2) inhibitor, which is the first licensed targeted agent for GC, shows restricted benefits owing to the low amplification rate (17–20%) of HER2 in GC patients [4].